Omicron science, promising news
June 17, 2026
17 min
Full
226 of 364

June 17, 2026
Omicron science, promising news
0:00 / 17:11
Excerpt playback isn’t available for this episode — use the full-episode link.
Search the Record
Moment search isn’t open for this episode yet
When it opens, you’ll be able to type any phrase and jump straight to the second it was said.
Dr John Campbell Episodes Around June 17, 2026
Episode 226 of 364 — walk the feed in the order it was published.
17:11This episodeOmicron science, promising news
Summary
New science explains South Africa's low rates of omicron severe disease
SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron
https://www.medrxiv.org/content/10.1101/2021.12.26.21268380v1
https://www.medrxiv.org/content/10.1101/2021.12.27.21268278v1
Institute of Infectious Disease and Molecular Medicine, University of Cape Town
SARS-CoV-2 Omicron variant has multiple Spike (S) protein mutations
These contribute to escape from the neutralizing antibody responses,
reducing vaccine protection from infection
We assessed the ability of T cells to react with Omicron spike
In participants who were vaccinated with Ad26.CoV2.S (J and J) (n = 20)
or BNT162b2 (Pfizer) (n = 15
or in unvaccinated convalescent COVID-19 patients (n = 15)
SARS-CoV-2-specific T cells play a key role in modulating COVID-19 severity and provide protective immunity
Results
70-80% of the CD4 and CD8 T cell response to spike was maintained across study groups
The magnitude of Omicron cross-reactive T cells was similar to that of the Beta and Delta variants
These results demonstrate that,
despite Omicron’s extensive mutations
and reduced susceptibility to neutralizing antibodies,
the majority of T cell response,
induced by vaccination or natural infection, cross- recognises the variant.
Well-preserved T cell immunity to Omicron,
is likely to contribute to protection from severe COVID-19,
supporting early clinical observations from South Africa.
Further explanation
The limited effect of Omicron’s mutations on the T cell response suggests that vaccination or prior infection may still provide substantial protection from severe disease.
Indeed, South Africa has reported a lower risk of hospitalisation and severe disease compared to the previous Delta wave
Cross-reactive T cell responses acquired through vaccination or infection may contribute to these apparent milder outcomes for Omicron.
The resilience of the T cell response demonstrated here also bodes well in the event that more highly mutated variants emerge in the future.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Episode details and artwork are published by the show’s own feed. Sentinel plays short cited excerpts and links every episode back to its publisher.





























